Scientific deep-dive
Semaglutide for Alcohol Use Disorder: Read the Placebo Arm
Heavy drinking days fell 41.1 points on semaglutide and 26.4 points on placebo. The drug's effect is the 13.7-point difference, and it is real, significant and a third of the number that will be quoted.
A 2026 randomized trial gave weekly semaglutide or placebo to 108 people with both alcohol use disorder and obesity. Heavy drinking days fell by 41.1 percentage points in the semaglutide group. That figure is going to travel, and it is the wrong one: the placebo group improved by 26.4 points, so the effect attributable to the drug is 13.7.[1]
The result, stated properly
| Group | Change | What it means |
|---|---|---|
| Semaglutide | −41.1 (95% CI −48.7 to −33.5) | The number that will be quoted |
| Placebo | −26.4 (95% CI −34.1 to −18.6) | The number that will not be |
| Treatment difference | −13.7 (95% CI −22.0 to −5.4), p=0.0015 | The effect of the drug |
The result is real. The confidence interval excludes zero comfortably and the trial also reported substantial effects on multiple secondary alcohol-related and physical outcomes.[1] A 13.7 point reduction in heavy drinking days is a meaningful clinical effect in a condition where treatments are few and modest.
The same trap, twice this week
This is the second trial we have written up in days where the placebo arm did most of the work in the headline number. In the fatty liver trial, steatohepatitis resolved in 62.9% on semaglutide — and in 34.3% on placebo.
When you see a single-arm percentage from a randomized trial, the other arm has been removed on purpose. Go and find it.
The pattern is worth internalizing because it is not a quirk of these two studies. Any condition where being watched helps — drinking, eating, adherence, symptom scores — will produce a large placebo response, and the drug’s contribution will be a fraction of the raw change.
How far this generalizes
- 108 participants, at a single center in Denmark. Small, and one health system.
- Everyone had obesity as well as alcohol use disorder. Whether the effect holds in people with alcohol use disorder and a normal BMI is untested, and it matters, because weight loss itself may be part of the mechanism.
- All were treatment-seeking. People who volunteer for an alcohol trial are not a random sample of people who drink heavily.
- 81% completed the intervention, which is good for this field and still leaves a fifth unaccounted for.
The direction is consistent with a growing body of preclinical and clinical work suggesting GLP-1 receptors are involved in reward and craving, which we cover in GLP-1s and substance use. Notably, a randomized trial in people who smoke missed both its primary endpoints — so this is not a uniform effect across substances.
What not to do with this
It is, though, a genuinely encouraging result in a field that badly needs them, and one worth raising with a doctor if it describes your situation.
Frequently Asked Questions
References
- 1.Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial The Lancet. 2026. PMID: 42070571.
Compare the sellers
Related research
GLP-1 Drugs and Opioid Use Disorder: What the Records Data Shows
Across 503,747 people with opioid use disorder, a GLP-1 or GIP prescription carried an adjusted overdose rate ratio of 0.60. In methadone-treated patients it was associated with a higher rate of remission. No randomized trial exists.
6 min read
GLP-1 Drugs and Quitting Smoking: What the Trials Actually Tested
The largest randomized trial found a GLP-1 added nothing to quit rates (63% against 65% on placebo) while holding post-cessation weight for as long as it was taken. A year later that advantage had gone too.
7 min read
Beyond the Scale: Blood Pressure, Lipids and What Else Changes
Pooling the individual records of 3,136 people, systolic blood pressure fell 4.95 mmHg further than placebo, and by about the same amount whether or not the person had hypertension.
7 min read
Does Semaglutide Slow Aging?
A trial reported semaglutide slowing epigenetic aging across several clocks. It was a post hoc analysis in an HIV-specific cohort over 32 weeks, and '−4.9 years per year' is a rate, not age removed.
5 min read
Dry Mouth on a GLP-1: Three Published Cases, and What to Tell Your Dentist
The published evidence that GLP-1 drugs cause dry mouth is three case reports. Nobody has measured how often it happens, but reduced saliva raises decay risk regardless of cause, which is the part worth acting on.
5 min read
Eating Too Little on a GLP-1: What the Deficiency Data Show
Across 480,825 adults, more than 60% were consuming below estimated requirements, vitamin D deficiency reached 13.6% at a year, and ferritin ran 26–30% below an active comparator.
7 min read
Where to get semaglutide (Ozempic / Wegovy) online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
YourEra
Semaglutide at $99/month, 63% below the typical price
From $99/mo
Get started →Gala
Moving between compounded and brand without changing seller
From $179/mo
Get started →CoreAge Rx
Semaglutide at $99/month, 48% below the typical price
From $99/mo
Get started →